招生专业
| 院系名称 | 专业大类 | 一级学科 | 专业代码/专业名称 | 学位类型 | 招生类型 |
| 交叉科学研究院 | 医学 | 中药学 | 100800/中药学 | 学术学位 | 博士/硕士 |
| 交叉科学研究院 | 医学 | 中药学 | 105600/中药学 | 专业学位 | 硕士 |
教育经历
1984.09-1988.07 第二军医大学药学院 获学士学位
1988.09-1991.07 第二军医大学药学院 获硕士学位
1995.09-1998.09上海医药工业研究院获博士学位
个人简介及研究方向
现任中国医学科学院药用植物研究所执行所长、海军军医大学现代中药研究中心主任。长期从事中药及复方的药效物质基础、中药的化学生物学以及创新药物研究。先后荣获国家杰出青年基金，教育部长江学者特聘教授，万人计划领军人才，中国科协求是杰出青年奖，百千万人才工程国家级人选，谈家桢生命科学奖，吴阶平医药创新奖，吴-杨奖，2022上海“最美科技工作者”等荣誉称号，享受国务院政府特殊津贴。
主要从事中药及复方的药效物质基础、中药的化学生物学以及创新药物研究。主持国家重点研发计划、863基金、国家科技重大专项、国家自然科学基金重点项目以及欧盟第七框架等基金40余项。在Chem Rev、Angew Chem Int Ed、STTT、PNAS等国际杂志发表SCI论文600多篇，引用超16000 次。获授权国内发明专利41项，国际专利7项，新药证书3项，临床批件5项。获国家科技进步二等奖3项、上海市科技进步一等奖2项及2023年度中医药十大学术进展等。担任国务院学位委员会学科评议组成员，国家药典委委员会天然药物专委会副主委，中国药学会微循环药学专委会主委，上海市药学会副理事长，《中国药典》英文版副主编，担任多本重要国际学术期刊的编委。
科研项目
序号 |
课题类型 |
项目时间 |
项目经费 （万元） |
备注 |
1 |
国家科技部重大项目 |
2021.01-2025.12 |
4000 |
主持 |
2 |
国家自然科学基金重点项目 |
2025.01-2029.12 |
231 |
主持 |
3 |
上海市三年行动计划 |
2021.09-2023.12 |
1309.44 |
主持 |
4 |
国家中医药多学科交叉创新团队项目 |
2021.01-2023.12 |
972 |
主持 |
代表性文章
1. DianpingYu#, Hongmei Hu#,Qing Zhang#,ChengjiWang#,MengtingXu, Hanchen Xu, Xiangxin Geng,Minchen Cai, Hongwei Zhang, Mengmeng Guo, Dong Lu, Hanchi Xu, Linyang Li, Xing Zhang, Sheng Lin*, Qun Wang*,Weidong Zhang*,Sanhong Liu*.Acevaltrate as a novel ferroptosis inducer with dual targets of PCBP1/2 and GPX4 in colorectal cancer.Signal Transduction and Targeted Therapy.2025. 10(1):211.IF: 52.7
2. Hu H#, Wang Q#, Yu D#, Tao X#, Guo M, Tian S, Zhang Q, Xu M, Geng X, Zhang H, Xu H, Li L, Xie S, Chen K, Zhu W, Li XW, Xu H*, Li B*,Zhang W*,Liu S*. Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual-Targeting BMI1 for Senescence Induction and CSN5 for PD-L1 Degradation.Advanced Science. 2025.12(7):e2413122.封面文章,IF:14.3
3. Tian S#, Xu M#, Geng X#, Fang J, Xu H, Xue X, Hu H, Zhang Q, Yu D, Guo M, Zhang H, Lu J, Guo C, Wang Q*,Liu S*,Zhang W*. Network Medicine-Based Strategy Identifies Maprotiline as a Repurposable Drug by Inhibiting PD-L1 Expression via Targeting SPOP in Cancer.Advanced Science. 2025. 12(1):e2410285.IF:14.3
4. Lin JY#, Wu Y#, Liang XH, Tang M, Sun X, Lu SX, Jin JM, Guo X, Wang B, Chen HZ*,Zhang WD*,Luan X*. A Self-Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple-Negative Breast Cancer Therapy.Adv Sci.2025, e2500311.IF:14.3
5. Lu S#, Zhang X#, Lin J, Liang R, Gong Y, Gao L, Cheng A, Lu X, Chen H, Wu Y *,Zhang W*,Luan X*. Diselenide bond-stapled β-hairpin peptide-loaded hydrogel system for boosting oncolytic immunotherapy.Chemical Engineering Journal. 2025,505:159076.IF:13.4
6. Liu Y#, Sun Q#, Guo J#, Yan L#, Yan Y, Gong Y, Lin J, Yuan H, Jin J, Wang B, Chen H, Zhang L*,Zhang W*,Luan X*. Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer.Cell Rep Med. 2025,6(1):101915.IF:11.7
7. Lu X*, Jin J*, Wu Y*, Lin J, Zhang X, Lu S, Zhang J, Zhang C, Ren M, Chen H*,Zhang W*,Luan X*. Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy.Bioact Mater. 2024,43:255-272.IF:18.0
8. Zhang X#, Wu Y#, Lin J, Lu S, Lu X, Cheng A, Chen H*,Zhang W*,Luan X*. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.Acta Pharm Sin B. 2024,14(9):3818-3833.IF:14.8
9. Yanyan Zhang#, Yun Huang#, Dianping Yu, Mengting Xu, Hongmei Hu, Qing Zhang, Minchen Cai, Xiangxin Geng, Hongwei Zhang, Jianhua Xia, Mengmeng Guo, Dong Lu, Hanchi Xu, Linyang Li, Xing Zhang, Qun Wang*,Sanhong Liu*,Weidong Zhang*. Demethylzeylasteral induces PD-L1 ubiquitin-proteasome degradation and promotes antitumor immunity via targeting USP22.Acta Pharm Sin B.2024.14(10):4312-4328.IF:14.8
10. Peng Y, Zhang Y, Fang R, Jiang H, Lan G, Xu Z, Liu Y, Nie Z, Ren L, Wang F,Zhang SD, Ma Y, Yang P, Ge HH,Zhang WD*, Luo C*, Li A*, He W*. TargetIdentification and Mechanistic Characterization of Indole Terpenoid Mimics:Proper Spindle Microtubule Assembly Is Essential for Cdh1-Mediated Proteolysisof CENP-A.Adv Sci (Weinh). 2024 Aug;11(29):e2305593.IF:14.3
11. Bian HT#, Liang XH#, Lu D#, Lin JY, Lu XC, Jin JM, Zhang LY, Wu Y*, Chen HZ*,Zhang WD*,Luan X*. In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77-PPARγInteraction and Its Anti-breast-cancer Efficacy.Adv Sci, 2024, 11(26):e2308435.IF:14.3
12. Guan X, Wang Y, Yu W, Wei Y, Lu Y, Dai E, Dong X, Zhao B, Hu C, Yuan L, LuanX, Miao K, Chen B, Cheng XD*,Zhang W*, Qin JJ*. Blocking Ubiquitin-SpecificProtease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoADesaturase.Adv Sci (Weinh). 2024 May;11(18):e2307899.IF:14.3
13. Gu WJ#, Liu XX#, Shen YW#, Gong YT, Chen YL, Lin J, Lu D, Zhang LJ, Chen HZ, Jin Y, Zhan ZJ*,Zhang WD*, Jin JM*,Luan X*. TRIM4 enhances small-molecule-induced neddylated-degradation of CORO1A for triple negative breast cancer therapy.Theranostics. 2024,14(18):7023-7041.IF:12.4
14. Qun Wang#, Jinxin Wang#, Dianping Yu#, Qing Zhang#, Hongmei Hu, Mengting Xu, Hongwei Zhang, Saisai Tian, Guangyong Zheng, Dong Lu, Jiajia Hu, Mengmeng Guo, Minchen Cai, Xiangxin Geng, Yanyan Zhang, Jianhua Xia, Xin Zhang, Ang Li,Sanhong Liu*,Weidong Zhang*. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.Cell Reports Medicine. 2024. 5(2):101357.封面文章，ESI前1%高被引论文，IF:11.7
15. Lu X#, Jin JM#, Wu Y#, Liu X, Liang X, Lin J, Sun Q, Qin JJ*,Zhang W*,Luan X*.Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.Med Res Rev. 2024, 44(2):812-832.IF:10.9
16. Jianhua Xia#, Mengting Xu#, Hongmei Hu, Qing Zhang,Dianping Yu, Minchen Cai, Xiangxin Geng, Hongwei Zhang, Yanyan Zhang, Mengmeng Guo, Dong Lu, Hanchi Xu, Linyang Li, Xing Zhang, Qun Wang*,Sanhong Liu*,Weidong Zhang*.5,7,4'-trimethoxyflavone triggers cancer cell PD-L1 ubiquitin-proteasome degradation and facilitates antitumor immunity by targeting HRD1.MedComm.2024. 5(7):e611.IF:10.7
17. Wu Y#, Lin JY#, Zhou YD, Liu HJ, Lu SX, Zhang XK, Guan YY, Nagle DG,Zhang WD*, Chen HZ*,Luan X*. Oncolytic Peptide-Nanoplatform Drives Oncoimmune Response and Reverses Adenosine-Induced Immunosuppressive Tumor Microenvironment.Adv Healthc Mater. 2024, e2303445.IF:10.0
18. Wan J#, Zhang Z#, Wu C, Tian S, Zang Y, Jin G, Sun Q, Wang P, Luan X, Yang Y,Zhan X, Ye LL, Duan DD*, Liu X*,Zhang W*. Astragaloside IV derivative HHQ16ameliorates infarction-induced hypertrophy and heart failure through degradationof lncRNA4012/9456. Signal Transduct Target Ther. 2023 Oct 19;8(1):414.IF:40.8，入选2023年度中医药十大学术进展。
19. Li X, Liao C, Xu Y, Lu QH, Chen S, Su L, Zou Y, Shao F, Lu W*,Zhang WD*, HuHG*. Configuration-Specific Antibody for Bacterial Heptosylation: An AntiadhesionTherapeutic Strategy.J Am Chem Soc. 2023 Jan 11;145(1):322-333.IF:14.5
20. Lin JY, Liu HJ, Wu Y, Jin JM, Zhou YD, Zhang H, Nagle DG, Chen HZ*,Zhang WD*,Luan X*. Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer.Small, 2023, e2207778.IF:13.0
21. Wendan Zhang#, Honghong Jiang#, Gaosong Wu#, Pengli Huang#, Haonan Wang*,Huazhang An*,Sanhong Liu*,Weidong Zhang*. The pathogenesis and potential therapeutic targets in sepsis.MedComm. 2023. 4: e418.IF=10.7
22. Chao Lv#, Yun Huang#, Qun Wang#, Chengji Wang#, Hongmei Hu, Hongwei Zhang, Dong Lu, Honghong Jiang, Ruling Shen,Weidong Zhang*,Sanhong Liu*. Ainsliadimer A induces ROS-mediated apoptosis in colorectal cancer cells via directly targeting peroxiredoxin 1 and 2.Cell Chemical Biology, 2023. 30: 295-307.封面文章,IF=9.0
23. Zhu C#, Guan X#, Zhang X#, Luan X, Song Z, Cheng X*,Zhang W*, Qin JJ*. TargetingKRAS mutant cancers: from druggable therapy to drug resistance.Mol Cancer. 2022Aug 4;21(1):159.IF:27.7
24. Qi S#, Guan X#, Zhang J#, Yu D, Yu X, Li Q, Yin W, Cheng XD*,Zhang W*, Qin JJ*.Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitorsuppresses pancreatic cancer growth and metastasis.Mol Cancer. 2022 Mar10;21(1):70.IF:27.7
25. Huang R#, Zhang LJ#, Jin JM#, Zhou YD, Zhang HW, Lv C, Lu D, Wu Y, Zhang H, Liu SH, Chen HZ*,Luan X*,Zhang WD*. Bruceine D inhibits HIF-1a-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/b-catenin interaction.Acta Pharm Sin B, 2021, 11(11):3481-3492.IF:14.8
26. Shen YW, Zhou YD, Chen HZ,Luan X*,Zhang WD*. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.Trends Cancer, 2021, 7(6):511-524.IF:14.3
27. Lin JY#, Jin JM#, Shen YW#, Zhang LJ, Gong G, Bian HT, Chen HZ, Nagle DG, Wu Y*,Zhang WD*,Luan X*. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.Theranostics, 2021, 11(17):8337-8349.IF:12.4
28. Luan X#, Wu Y#, Shen YW, Zhang H, Zhou YD., Chen HZ, Nagle DG*,Zhang WD*. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat Prod Rep, 2021, 38(1):7-17.IF:10.2，封面论文。
29. Li X, Chen S,Zhang WD*, Hu HG*. Stapled Helical Peptides Bearing DifferentAnchoring Residues.Chem Rev. 2020 Sep 23;120(18):10079-10144.IF:51.5
30. Shen YW, Zhou YD,Luan X*,Zhang WD*. Blocking CTGF-Mediated Tumor-Stroma Interplay in Pancreatic Cancer.Trends Mol Med, 2020, 26(12):1064-1067.IF:12.8
31. Jin JM#, Wu Y#, Chen JJ, Shen YW, Zhang LJ, Zhang H, Chen LL, Yuan HB, Chen HZ,Zhang WD*,Luan X*. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.Theranostics,2020,10(22):10141-10153.IF:12.4，封面论文。